Cholinesterase inhibitors: Beyond alzheimers disease

Expert Review of Neurotherapeutics

Volumn 10, Issue 11, 2010, Pages 1699-1705

  Larner, Aj ^a  

^a WALTON CENTRE FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

Author keywords

Alzheimers disease; cholinesterase inhibitors; delirium; epilepsy; frontotemporal dementia; Huntingtons disease; multiple sclerosis; parkinsonian syndromes; traumatic brain injury; treatment; vascular dementia

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; PLACEBO; RIVASTIGMINE;

ALZHEIMER DISEASE; AMNESIA; ANTERIOR COMMUNICATING ARTERY; BIPOLAR DISORDER; BRADYCARDIA; CADASIL; CLINICAL PRACTICE; CLINICAL TRIAL; COGNITIVE DEFECT; DELIRIUM; DEMENTIA; DISEASE SEVERITY; DOWN SYNDROME; DRUG TOXICITY; DRUG USE; EPILEPSY; FRONTOTEMPORAL DEMENTIA; HIP FRACTURE; HUMAN; HUNTINGTON CHOREA; LEWY BODY; LOW DRUG DOSE; MULTIINFARCT DEMENTIA; MULTIPLE SCLEROSIS; NARCOLEPSY; NAUSEA; PARKINSON DISEASE; PRACTICE GUIDELINE; PROGRESSIVE SUPRANUCLEAR PALSY; REVIEW; SCHIZOPHRENIA; SIDE EFFECT; SINUS NODE; SLEEP APNEA SYNDROME; SLEEP DISORDER; SYNCOPE; SYSTEMIC LUPUS ERYTHEMATOSUS; TRAUMATIC BRAIN INJURY; TREATMENT INDICATION; TREMOR; VOMITING;

CHOLINESTERASE INHIBITORS; COGNITION DISORDERS; DEMENTIA; DOWN SYNDROME; HUMANS; MULTIPLE SCLEROSIS; PARKINSON DISEASE; SCHIZOPHRENIA;

EID: 78049470959     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/ern.10.105     Document Type: Review

References (73)

1. Lanctôt KL, Hermann N, Yau KK et al. Effcacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis. CMAJ 169, 557-564 (2003).
2. Ritchie CW, Ames D, Clayton T, Lai R. Meta-analysis of randomized trials of the effcacy and safety of donepezil, galantamine and rivastigmine for the treatment of Alzheimer disease. Am. J. Geriatr. Psychiatry 12, 358-369 (2004).
3. Whitehead A, Perdomo C, Pratt RD, Birks J, Wilcock GK, Evans JG. Donepezil for the symptomatic treatment of patients with mild to moderate Alzheimer's disease: a meta-analysis of individual patient data from randomised controlled trials. Int. J. Geriatr. Psychiatry 19, 624-633 (2004).
4. Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst. Rev. (1), CD005593 (2006).
5. Takeda A, Loveman E, Clegg A et al. A systematic review of the clinical effectiveness of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in Alzheimer's disease. Int. J. Geriatr. Psychiatry 21, 17-28 (2006).
6. Birks J, Harvey RJ. Donepezil for dementia due to Alzheimer's disease. Cochrane Database Syst. Rev. (1), CD001190 (2006).
7. Loy C, Schneider L. Galantamine for Alzheimer's disease and mild cognitive impairment. Cochrane Database Syst. Rev. (1), CD001747 (2006).
8. Birks J, Grimley Evans J, Iakovidou V, Tsolaki M, Holt FE. Rivastigmine for Alzheimer's disease. Cochrane Database Syst. Rev. (2), CD001191 (2006).
9. Lopez OL, Becker JT, Saxton J, Sweet RA, Klunk W, Dekosky ST. Alteration of a clinically meaningful outcome in the natural history of Alzheimer's disease by cholinesterase inhibition. J. Am. Geriatr. Soc. 53, 83-87 (2005).
10. Larner AJ. Do cholinesterase inhibitors alter the course of dementia? Prog. Neurol. Psychiatry 11(5), 26-28 (2007).
11. Inestrosa NC, Alvarez A, Perez CA et al. Acetylcholinesterase accelerates assembly of amyloid b-peptides into Alzheimer's fbrils: possible role of the peripheral site of the enzyme. Neuron 16, 881-891 (1996).
12. Larner AJ. Neuropsychological Neurology: the Neurocognitive Impairments of Neurological Disorders. Cambridge University Press, Cambridge, UK (2008).
13. Petersen RC, Thomas RG, Grundman M et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N. Engl. J. Med. 352, 2379-2388 (2005).
14. Birks J, Flicker L. Donepezil for mild cognitive impairment. Cochrane Database Syst. Rev. (3), CD006104 (2006).
15. Feldman HH, Ferris S, Winblad B et al. Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study. Lancet Neurol. 6, 501-512 (2007).
16. Winblad B, Gauthier S, Scinto L et al. Safety and effcacy of galantamine in subjects with mild cognitive impairment. Neurology 70, 2024-2035 (2008).
17. Mohan M, Carpenter PK, Bennett C. Donepezil for dementia in people with Down syndrome. Cochrane Database Syst. Rev. (1), CD007178 (2009).
18. Mohan M, Carpenter PK, Bennett C. Rivastigmine for dementia in people with Down syndrome. Cochrane Database Syst. Rev. (1), CD007658 (2009).
19. Mohan M, Carpenter PK, Bennett C. Galantamine for dementia in people with Down syndrome. Cochrane Database Syst. Rev. (1), CD007656 (2009).
20. Winblad B, Black SE, Homma A et al. Donepezil treatment in severe Alzheimer's disease: a pooled analysis of three clinical trials. Curr. Med. Res. Opin. 25, 2577-2587 (2009).
21. McKeith I, Del Ser T, Spano P et al. Effcacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet 356, 2031-2036 (2000).
22. Wesnes KA, McKeith IG, Ferrara R et al. Effects of rivastigmine on cognitive function in dementia with Lewy bodies: a randomized placebo-controlled international study using the cognitive drug research computerized assessment system. Dement. Geriatr. Cogn. Disord. 13, 183-192 (2002).
23. Grace J, Daniel S, Stevens T et al. Long-term use of rivastigmine in patients with dementia with Lewy bodies: an open-label trial. Int. Psychogeriatr. 13, 199-205 (2001).
24. Wild R, Pettit T, Burns A. Cholinesterase inhibitors for dementia with Lewy bodies. Cochrane Database Syst. Rev. (3), CD003672 (2003).
25. Edwards K, Royall D, Hershey L et al. Effcacy and safety of galantamine in patients with dementia with Lewy bodies: a 24-week open-label study. Dement. Geriatr. Cogn. Disord. 23, 401-405 (2007).
26. Aarsland D, Laake K, Larsen JP et al. Donepezil for cognitive impairment in Parkinson's disease: a randomised controlled study. J. Neurol. Neurosurg. Psychiatry 72, 708-712 (2002).
27. Leroi I, Brandt J, Reich SG et al. Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkinson's disease. Int. J. Geriatr. Psychiatry 19, 1-8 (2004).
28. Leroi I, Collins D, Marsh L. Non-dopaminergic treatment of cognitive impairment and dementia in Parkinson's disease: a review. J. Neurol. Sci. 248, 104-114 (2006).
29. Emre M, Aarsland D, Albanese A et al. Rivastigmine for dementia associated with Parkinson's disease. N. Engl. J. Med. 351, 2509-2518 (2004).
30. Maidment I, Fox C, Boustani M. Cholinesterase inhibitors for Parkinson's disease dementia. Cochrane Database Syst. Rev. (1), CD004747 (2006).
31. Almaraz AC, Driver-Dunckley ED, Woodruff BK et al. Effcacy of rivastigmine for cognitive symptoms in Parkinson disease with dementia. Neurologist 15, 234-237 (2009).
32. Dubois B, Tolosa E, Kulisevsky J et al. Effcacy and safety of donepezil in the treatment of Parkinson's disease patients with dementia. Neurodegen. Dis. 4(Suppl. 1), 90 (2007).
33. National Collaborating Centre for Chronic Conditions. Parkinson's Disease: National Clinical Guideline for Diagnosis and Management in Primary and Secondary Care. Royal College of Physicians, London, UK (2006).
34. Litvan I, Phipps M, Pharr VL, Hallett M, Grafman J, Salazar A. Randomized placebo-controlled trial of donepezil in patients with progressive supranuclear palsy. Neurology 57, 467-473 (2001).
35. Erkinjuntti T, Roman G, Gauthier S, Feldman H, Rockwood K. Emerging therapies for vascular dementia and vascular cognitive impairment. Stroke 35, 1010-1017 (2004).
36. Malouf R, Birks J. Donepezil for vascular cognitive impairment. Cochrane Database Syst. Rev. (1), CD004395 (2004).
37. Roman GC, Wilkinson DG, Doody RS, Black SE, Salloway SP, Schindler RJ. Donepezil in vascular dementia: combined analysis of two large-scale trials. Dement. Geriatr. Cogn. Disord. 20, 338-344 (2005).
38. Craig D, Birks J. Rivastigmine for vascular cognitive impairment. Cochrane Database Syst. Rev. (2), CD004744 (2005).
39. Craig D, Birks J. Galantamine for vascular cognitive impairment. Cochrane Database Syst. Rev. (1), CD004746 (2006).
40. Kavirajan H, Schneider LS. Effcacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials. Lancet Neurol. 6, 782-792 (2007).
41. Kwon JC, Kim EG, Kim JW et al. A multicenter, open-label, 24-week follow-up study for effcacy on cognitive function of donepezil in Binswanger-type subcortical vascular dementia. Am. J. Alzheimers Dis. Other Demen. 24, 293-301 (2009).
42. Mesulam M, Siddique T, Cohen B. Cholinergic denervation in a pure multi-infarct state. Observations in CADASIL. Neurology 60, 1183-1185 (2003).
43. Dichgans M, Markus HS, Salloway S et al. Donepezil in patients with subcortical vascular cognitive impairment: a randomised double-blind trial in CADASIL. Lancet Neurol. 7, 310-318 (2008).
44. Wright RA, Boeve BF, Malec JF. Amnesia after basal forebrain damage due to anterior communicating artery aneurysm rupture. J. Clin. Neurosci. 6, 511-515 (1999).
45. Lyketsos CG. Brain tumors, systemic lupus erythematosus, HIV/AIDS, and Wilson's disease. In: Psychiatric Aspects of Neurologic Diseases. Practical Approaches to Patient Care. Lyketsos CG, Rabins PV, Lipsey JR, Slavney PR (Eds). Oxford University Press, NY, USA, 305-320 (2008).
46. Davies M, Larner AJ. Clinical misdiagnosis of Alzheimer's disease: getting it wrong again. Eur. J. Neurol. 16(Suppl. 3), 351 (abstract 2036) (2009).
47. Moretti R, Torre P, Antonello RM, Cattaruzza T, Cazzato G, Bava A. Rivastigmine in frontotemporal dementia: an open-label study. Drugs Aging 21, 931-937 (2004).
48. Mendez MF, Shapira JS, McMurtray A, Licht E. Preliminary fndings: behavioural worsening on donepezil in patients with frontotemporal dementia. Am. J. Geriatr. Psychiatry 15, 84-87 (2007).
49. Kertesz A, Morlog D, Light M et al. Galantamine in frontotemporal dementia and primary progressive aphasia. Dement. Geriatr. Cogn. Disord. 25, 178-185 (2008).
50. Kertesz A. Clinical features and diagnosis of frontotemporal dementia. In: Dementia in Clinical Practice. Giannakopoulos P, Hof PR (Eds). Karger, Basel, Switzerland, 140-148 (2009).
51. Cubo E, Shannon KM, Tracy D et al. Effect of donepezil on motor and cognitive function in Huntington disease. Neurology 67, 1268-1271 (2006).
52. Rosenblatt A. Huntington's disease. In: Psychiatric Aspects of Neurologic Diseases. Practical Approaches to Patient Care. Lyketsos CG, Rabins PV, Lipsey JR, Slavney PR (Eds). Oxford University Press, NY, USA, 251-265 (2008).
53. Greene YM, Tariot PN, Wishart H et al. A 12-week open trial of donepezil hydrochloride in patients with multiple sclerosis and associated cognitive impairments. J. Clin. Psychopharmacol. 20, 350-356 (2000).
54. Krupp LB, Christodoulou C, Melville P, Scherl WF, MacAllister WS, Elkins LE. Donepezil improved memory in multiple sclerosis in a randomized clinical trial. Neurology 63, 1579-1585 (2004).
55. Parry AMM, Scott RB, Palace J, Smith S, Matthews PM. Potentially adaptive functional changes in cognitive processing for patients with multiple sclerosis and their acute modulation by rivastigmine. Brain 126, 2750-2760 (2003).
56. Shaygannejad V, Janghorbani M, Ashtari F, Zanjani HA, Zakizade N. Effects of rivastigmine on memory and cognition in multiple sclerosis. Can. J. Neurol. Sci. 35, 476-481 (2008).
57. Fisher RS, Bortz JJ, Blum DE, Duncan B, Burke H. A pilot study of donepezil for memory problems in epilepsy. Epilepsy Behav. 2, 330-334 (2001).
58. Hamberger MJ, Palmese CA, Scarmeas N, Weintraub D, Choi H, Hirsch LJ. A randomized double-blind placebo-controlled trial of donepezil to improve memory in epilepsy. Epilepsia 48, 1283-1291 (2007).
59. Griffth HR, Martin R, Andrews S et al. The safety and tolerability of galantamine in patients with epilepsy and memory diffculties. Epilepsy Behav. 13, 376-380 (2008).
60. Overshott R, Karim S, Burns A. Cholinesterase inhibitors for delirium. Cochrane Database Syst. Rev. (1), CD005317 (2008).
61. Liptzin B, Laki A, Garb JL, Fingeroth R, Krushell R. Donepezil in the prevention and treatment of post-surgical delirium. Am. J. Geriatr. Psychiatry 13, 1100-1106 (2005).
62. Sampson EL, Raven PR, Ndhlovu PN et al. A randomized, double-blind, placebo-controlled trial of donepezil hydrochloride (Aricept) for reducing the incidence of postoperative delirium after elective total hip replacement. Int. J. Geriatr. Psychiatry 22, 343-349 (2007).
63. Ballesteros J, Guemes I, Ibarra N, Quemada JI. The effectiveness of donepezil for cognitive rehabilitation after traumatic brain injury: a systematic review. J. Head Trauma Rehabil. 23, 171-180 (2008).
64. Moraes W, Poyares D, Sukys-Claudino L, Guilleminault C, Tufk S. Donepezil improves obstructive sleep apnea in Alzheimer disease: a double-blind, placebo-controlled study. Chest 133, 677-683 (2008).
65. Moraes W, Sukys-Claudino L, Poyares D, Tufk S. Donepezil treatment for sleep apnoea in non-demented patients. Eur. J. Neurol. 16(Suppl. 3), 620 (abstract 2827) (2009).
66. Staszewski J, Stepien A. Effcacy of rivastigmine treatment in narcolepsy: report of 2 cases. Eur. J. Neurol. 16(Suppl. 3), 624 (abstract 2841) (2009).
67. Ribeiz SR, Bassitt DP, Arrais JA, Avila R, Steffens DC, Bottino CM. Cholinesterase inhibitors as adjunctive therapy in patients with schizophrenia and schizoaffective disorder: a review and meta-analysis of the literature. CNS Drugs 24, 303-317 (2010).
68. Iosifescu DV, Moore CM, Deckersbach T et al. Galantamine-ER for cognitive dysfunction in bipolar disorder and correlation with hippocampal neuronal viability: a proof-of-concept study. CNS Neurosci. Ther. 15, 309-319 (2009).
69. Shaw EG, Rosdhal R, D'Agostino RB Jr et al. Phase II study of donepezil in irradiated brain tumor patients: effect on cognitive function, mood, and quality of life. J. Clin. Oncol. 24, 1415-1420 (2006).
70. Noyan MA, Elbi H, Aksu H. Donepezil for anticholinergic drug intoxication: a case report. Prog. Neuropsychopharmacol. Biol. Psychiatry 27, 885-887 (2003).
71. Alisky JM. Could cholinesterase inhibitors and memantine alleviate HIV dementia? J. Acquir. Immune Defc. Syndr. 38, 113-114 (2005).
72. Gill SS, Anderson GM, Fischer HD et al. Syncope and its consequences in patients with dementia receiving cholinesterase inhibitors: a population-based cohort study. Arch. Intern. Med. 169, 867-873 (2009).
73. Larner AJ. Transdermal rivastigmine for Alzheimer's disease: skin deep or scratching the surface? Int. J. Clin. Pract. 64, 534-536 (2010).